Active	Status	Sponsor type	Region	Phase	Filter
9 Active 2 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gu, Ke
ChESS, NCT03622827: Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer	Recruiting	2	120	RoW	Chemoradiotherapy+ Endostar	Nanjing Medical University, Second Affiliated Hospital of Soochow University	Uterine Cervical Neoplasms	07/23	07/25
NCT05115500: ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)	Not yet recruiting	2	55	RoW	ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2	Second Affiliated Hospital of Soochow University	Carcinoma, Solid Tumor	10/24	04/25
Xue, Jing
NCT04981145: The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome	Recruiting	4	78	RoW	Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets	Second Affiliated Hospital, School of Medicine, Zhejiang University	Primary Sjögren's Syndrome	12/24	07/25
NCT04127747: Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus	Recruiting	4	110	RoW	Standard dose of rituximab, Individualized dose of rituximab	Second Affiliated Hospital, School of Medicine, Zhejiang University	Autoimmune Diseases	12/22	07/23
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
NCT06375005: Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis	Not yet recruiting	2	38	RoW	Telitacicept, Taiai for commercial name, Mycophenolate Mofetil, MMF	Second Affiliated Hospital, School of Medicine, Zhejiang University	Diffuse Cutaneous Systemic Sclerosis	08/25	12/26
NCT05872724: Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)	Recruiting	2	32	RoW	Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab, Chemoradiotherapy (small pelvic) + Zimberelimab	Suzhou Municipal Hospital	Cervical Cancer	01/28	12/28
CAPSTONE, NCT05230017: Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks	Recruiting	N/A	2000	RoW		Peking Union Medical College Hospital	Anti Phospholipid Syndrome	12/26	12/26
NCT04923074: the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasculitis	Recruiting	N/A	50	RoW	diffusion tensor imaging(DTI) evaluation	Second Affiliated Hospital, School of Medicine, Zhejiang University	ANCA Associated Vasculitis	07/23	07/23